Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5mg/25mg and 250mg/100mg, the generic version of GlaxoSmithKline's Malarone tablets.
Subscribe to our email newsletter
Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prophylaxis of Plasmodium falciparum malaria and the treatment of acute, uncomplicated P. falciparum malaria.
Atovaquone and Proguanil Hydrochloride tablets, 62.5mg/25mg and 250mg/100mg, had US sales of approximately $89.4m for the 12 months ending 31 March 2014, according to IMS Health.
Currently, Mylan has 299 ANDAs pending FDA approval representing $105.2bn in annual brand sales, according to IMS Health. A total of 41 of these pending ANDAs are potential first-to-file opportunities, representing $25.4bn in annual brand sales, for the 12 months ending 31 December 2013, according to IMS Health.